SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study

Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma, where survival has been remarkably improved by use of protocols including high dose cytarabine, rituximab and autologous stem cell transplantation, such as the Nordic MCL2/3 protocols. In 2008, a MCL international prognostic index (MIPI) w...

Full description

Bibliographic Details
Main Authors: Nordström, Lena, Sernbo, Sandra, Eden, Patrik, Grønbæk, Kirsten, Kolstad, Arne, Räty, Riikka, Karjalainen, Marja-Liisa, Geisler, Christian, Ralfkiær, Elisabeth, Sundström, Christer, Laurell, Anna, Delabie, Jan, Ehinger, Mats, Jerkeman, Mats, Ek, Sara
Format: Online
Language:English
Published: BlackWell Publishing Ltd 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282019/